 | Up a level |
Toh, H. C. and Yang, M. -h. and Wang, H. -m. and Hsieh, C. Y. and Chitapanarux, I. and Ho, K. F. and Hong, R. -l. and Ang, M. K. and Colevas, A. D. and Sirachainan, E. and Lertbutsayanukul, C. and Ho, G. F. and Nadler, E. and Algazi, A. and Lulla, P. and Wirth, L. J. and Wirasorn, K. and Liu, Y. C. and Ang, S. F. and Low, S. H. J. and Tho, L. M. and Hasbullah, H. H. and Brenner, M. K. and Wang, W. -w. and Ong, W. S. and Tan, S. H. and Horak, I. and Ding, C. and Myo, A. and Samol, J. (2024) Gemcitabine, carboplatin, and Epstein-Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized phase III trial. Annals of Oncology, 35 (12). pp. 1181-1190. ISSN 0923-7534, DOI https://doi.org/10.1016/j.annonc.2024.08.2344.
